Currently out of the existing stock ratings of Arlinda Lee, 79 are a BUY (89.77%), 9 are a HOLD (10.23%).

Arlinda Lee

Work Performance Price Targets & Ratings Chart

Analyst Arlinda Lee, carries an average stock price target met ratio of 66.7% that have a potential upside of 37.67% achieved within 252 days. Previously, Arlinda Lee worked at CANACCORD.

Arlinda Lee’s has documented 178 price targets and ratings displayed on 27 stocks. The coverage was on Healthcare, Consumer Cyclical, Communication Services sectors.

Most recent stock forecast was given on VOD, Vodafone Group PLC ADR at 12-Oct-2023.

Wall Street Analyst Arlinda Lee

Analyst best performing recommendations are on NIO (NIO ADR).
The best stock recommendation documented was for NIO (NIO ADR) at 3/8/2021. The price target of $38.8 was fulfilled within 1 day with a profit of $3.59 (10.2%) receiving and performance score of 101.96.

Average potential price target upside

of $57.47 (48.62%) on NLTX (NEOLEUKIN THERAPEUTICS).
of $27.83 (49.05%) on RARE (ULTRAGENYX).
of $133.05 (8.62%) on NKTR (NEKTAR THERAPEUTICS).

BCYC Bicycle Therapeutics Ltd BNTX BioNTech SE BPMC Blueprint Medicines Corp CRSP Crispr Therapeutics AG DCPH Deciphera Pharmaceuticals LLC HALO Halozyme Therapeutics HARP Harpoon Therapeutics NIO Nio ADR NKTR Nektar Therapeutics RARE Ultragenyx TPTX Turning Point Therapeutics CELC Celcuity LLC KPTI Karyopharm Therapeutics DCTH Delcath Systems ORAN Orange SA ADR XFOR X4 Pharmaceuticals XNCR Xencor ZNH China Southern Airlines Co Ltd ADR VOD Vodafone Group PLC ADR CEA China Eastern Airlines Ltd DTEGY Deutsche Telekom AG ADR LBTYA Liberty Global PLC TEF Telefonica SA ADR TLSNY Telia Company AB ADR ZYME Zymeworks Common Stock ZYNE Zynerba Pharmaceuticals NLTX Neoleukin Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Gregory Renza (TRUIST)